Tetraphase falls on Phase III cUTI miss

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) lost $3.28 (60%) to $2.15 on Wednesday after reporting that IV eravacycline (TP-434) missed the co-primary endpoints in

Read the full 225 word article

User Sign In